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Abstract
Background: Epigenetics changes have been shown to be affected by cigarette smoking. Cigarette smoke
(CS)-mediated DNA methylation can potentially affect several cellular and pathophysiological processes, acute
exacerbations, and comorbidity in the lungs of patients with chronic obstructive pulmonary disease (COPD).
We sought to determine whether genome-wide lung DNA methylation profiles of smokers and patients with
COPD were significantly different from non-smokers. We isolated DNA from parenchymal lung tissues of
patients including eight lifelong non-smokers, eight current smokers, and eight patients with COPD and
analyzed the samples using Illumina’s Infinium HumanMethylation450 BeadChip.
Results: Our data revealed that the differentially methylated genes were related to top canonical pathways
(e.g., G beta gamma signaling, mechanisms of cancer, and nNOS signaling in neurons), disease and disorders
(organismal injury and abnormalities, cancer, and respiratory disease), and molecular and cellular functions
(cell death and survival, cellular assembly and organization, cellular function and maintenance) in patients
with COPD. The genome-wide DNA methylation analysis identified suggestive genes, such as NOS1AP, TNFAIP2, BID,
GABRB1, ATXN7, and THOC7 with DNA methylation changes in COPD lung tissues that were further validated by
pyrosequencing. Pyrosequencing validation confirmed hyper-methylation in smokers and patients with COPD as
compared to non-smokers. However, we did not detect significant differences in DNA methylation for TNFAIP2, ATXN7,
and THOC7 genes in smokers and COPD groups despite the changes observed in the genome-wide analysis.
Conclusions: Our study suggests that DNA methylation in suggestive genes, such as NOS1AP, BID, and GABRB1 may be
used as epigenetic signatures in smokers and patients with COPD if the same is validated in a larger cohort. Future
studies are required to correlate DNA methylation status with transcriptomics of selective genes identified in this study
and elucidate their role and involvement in the progression of COPD and its exacerbations.
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Background
Cigarette smoking is the main etiological factor in the
pathogenesis of chronic obstructive pulmonary disease
(COPD). Several mechanisms have been proposed in the
pathogenesis of COPD, such as oxidative stress, inflamma-
tion, protease/antiprotease, epigenetics, apoptosis, and
cellular senescence [1]. Cigarette smoke (CS) is known to
affect the transcriptional regulation of upstream and
downstream target genes involved in different canonical
pathways that are implicated in the progression of COPD.
However, not all the alterations in the pathogenesis of
COPD, e.g., steroid resistance, acute exacerbations, and
comorbidity, can be explained by transcriptional changes
or cellular abnormalities alone [2, 3].
Epigenetic mechanisms, specifically methylation status
of the DNA at specific CpG sites, are known to play a
crucial role in several chronic inflammatory diseases in-
cluding cancer and aging [2, 3]. DNA methylation plays
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an important role in transcriptional regulation, e.g., gene
silencing [1, 2]. Environmental and genetic factors, such
as CS exposure, diet, genetic variation, and aging, trigger
oxidative stress that can affect the promoter CpG
methylation by recruiting methyl CpG binding protein 2
and DNA methyltransferases onto various promoters
[1, 2]. Alteration in the methylation status of the promoter
affects expression of tumor suppressor, oncogenes, and
pro- and anti-inflammatory genes [2]. Previously, studies
were conducted using sputum, whole blood, peripheral
blood leukocytes, WBCs, alveolar macrophages, small air-
way epithelium, lung tissues, including buccal brushings,
and bronchial brushings of small airways to investigate
DNA methylation sites associated with smokers and pa-
tients with COPD [4–15]. Different methods of DNA
methylation profiling were conducted to assess the epi-
genetic disruption in key genes and canonical pathways
associated with smoking history and COPD status [5–15].
However, the DNA methylation profiling in parenchymal
lung tissues of smokers and patients with COPD and their
relationship between gene-specific DNA methylation,
smoking, and COPD disease progression remains unclear.
DNA methylation is a reversible gene regulatory modi-
fication which is shown to be altered by tobacco smoke.
Current smokers with a gene-specific DNA hyper- or
hypo-methylation can be highly susceptible to disease
development based on the patterns of genomic DNA
methylation profiles. A growing body of evidence sug-
gests that DNA methylation status in gene promoters
can be used as a novel epigenetic biomarker for
smoking-related chronic lung diseases, such as COPD
and its exacerbations as well as lung cancer [10, 16–19].
The effects of differential DNA methylation patterns me-
diated by tobacco smoke, particularly in lung tissues from
healthy lifelong non-smokers in comparison with smokers
and patients with COPD, remains unclear. In the present
study, we used a genome-wide DNA methylation analysis
(Illumina’s Infinium 450K BeadChip array) combined with
pyrosequencing approaches to identify novel suggestive
genes as epigenetic signatures of DNA methylation in lung
tissues. This study could offer promise as measures of to-
bacco smoke exposure or toxicity and ultimately serve as
an indicator for the susceptibility, progression, pathogen-
esis, and exacerbations of smoking-related chronic lung
diseases. Some of the results have been reported in the
form of an abstract [20].
Methods
Ethics statement and scientific rigor/reproducibility
The lung tissue specimens from normal, lifelong non-
smokers, smokers, and patients with COPD were col-
lected by the Department of Medicine and Pathology,
Helsinki University Central Hospital. The clinical char-
acteristics of the subjects/patients used in this study are
summarized (Table 1). We used a rigorous/robust and
unbiased approach throughout the experimental plans
and during analyzing the data so as to ensure that our
data are reproducible along with by full and detailed
reporting of both methods and raw/analyzed data. All
the key biological and/or chemical resources that are
used in this study were validated and authenticated
(methods and resources) and are of scientific standard
from commercial sources. Our results adhere to NIH
standards of reproducibility and scientific rigor.
Human lung tissues
Lung tissue specimens from 24 subjects/patients including
8 lifelong non-smokers, 8 current smokers with normal
lung function, and 8 patients with COPD undergoing re-
section for suspected lung tumor (either malignant or
nonmalignant-local carcinoma or hamartoma) or lung
transplantation from the Department of Medicine and
Pathology, Helsinki University Hospital as described in
our previous study [21, 22]. Tumor-free peripheral lung
tissues were immediately stored at −80 °C for DNA
extraction. The clinical characteristics of the subjects/
patients used in this study are provided (Table 1).
Genomic DNA isolation and DNA methylation profiling
Lung tissues were collected snap frozen and stored
at −80 °C. Genomic DNA was extracted from lung tissue
using the Qiagen DNAeasy kit (Qiagen, Valencia, AC) ac-
cording to the manufacturer’s instructions. Briefly, 1 μg
genomic DNA was bisulfite-converted using EZ DNA
Methylation Kit (Zymo Research, Irvine, CA). The
bisulfite-converted DNA samples were assayed using
Infinium HumanMethylation450 BeadChip array from
Table 1 General clinical characteristics of non-smokers, smokers,
and COPD patients
Parameters Non-smokers Smokers COPD
Number of subjects 8 8 8
M:F ratio 6:2 7:1 5:3
Male:female (%) (75%:25%) (87.5%:12.5%) (62.5%:37.5%)
Age, year 62.62 ± 1.87 61 ± 2.33 56.1 ± 2.57
(55–69) (52–71) (45–63)
Smoking, pack years – 27.14 ± 5.96*** 28.8 ± 4.32***
(10–50)a (10–43)a
FEV1 % predicted 100.28 ± 5.55 88.75 ± 4.04 23 ± 4.41
***; ###
(81–124)b (68–102) (10–43)
FEV1/FVC % 0.79 ± 0.01 0.81 ± 0.02 0.33 ± 0.03
***; ###
(0.73–0.85)b (0.75–0.95) (0.25–0.5)
aNo pack years details for one subject in the smokers and COPD groups
bNo FEV1 % predicted (one subject) and FEV1/FVC % values (two subjects) in
the non-smokers group
***P < 0.001 vs. non-smokers, ###P < 0.001 vs. smokers
M:F Male to Female ratio, FEV1 forced expiratory volume in 1 s
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Illumina (San Diego, CA). A total of 485,512 CpG sites
were probed for each sample that was processed as per
the manufacturer’s protocol. Image and data analysis of
the BeadChips were performed using the Illumina iScan
Reader. The image data is then transferred to Illumina
GenomeStudio data processing, validation of assay con-
trols, and report generation using the methylation mod-
ule. The level of methylation for the interrogated locus
is determined by calculating the ratio of the fluorescent
signals from methylated vs. unmethylated sites. From
the genome-wide DNA methylation data, we identified
specific genes based on their top canonical pathways
and biological functions by functional network analysis
using ingenuity pathway analysis (IPA) that were sig-
nificantly hyper-methylated in lung tissues of smokers
and patients with COPD compared to non-smokers for
validation by pyrosequencing.
Statistical approaches for DNA methylation analysis and
functional network analysis
Quality control (QC) was first performed on DNA
methylation data by filtering out probes with any of the
following conditions: (1) Missing methylation beta value
in any of the samples, (2) probes on X and Y chromo-
some, (3) any probes associated with SNP, (4) any probes
that cannot unambiguously mapped to the Human Ref-
erence Genome, and (5) ensured at least 75% samples
with detection P value <0.05 in each of the three groups
(Non-smokers, NS; Smokers, S; and COPD, C). After the
above QC filtering, we have a total of 276,260 probes.
Second, the raw DNA methylation level data (beta
values) were normalized using the SWAN normalization
method in minfi package [23]. The SWAN method was
able to correct the bias introduced by the two types of
probes in the Illumina 450K platform due to chemistry
differences in those probes [24]. The quality-controlled
and normalized DNA methylation data from the COPD,
smoker, and non-smoker groups conducted at two dif-
ferent time points were then combined together. A low
DNA methylation level filtering was applied to the post-
preprocessed DNA methylation data to filter out DNA
methylation loci with maximum methylation level below
0.15. The difference in methylation levels between dif-
ferent groups at each remained methylation loci was
examined using a general linear model approach after
adjusting the time effect in the model using the limma
package in R/Bioconductor [25]. The estimates of the
group differences were examined using a moderated t
statistics with empirical Bayes approach to shrink the
standard deviations for obtaining robust estimates. The
top candidate genes/probes were selected based on un-
corrected P values since none of the CpG sites were
significant after adjusting the raw P values using the
Benjamini-Hochberg procedure. Although those top
candidate gene/probes were selected based on uncor-
rected P values, they did indicate the observed differ-
ences between groups that may likely be true positives
and possibly reach statistical significance after multipli-
city adjustment given a larger sample size which will be
further evaluated in future studies. Linear contrasts
within the general linear models were conducted for
pairwise comparisons between groups (COPD vs. smoker;
COPD vs. non-smoker; smoker vs. non-smoker). Top
candidates in each pairwise comparison were selected
by test statistics and P values (with unadjusted raw P
value P < 0.001) from comparisons. Venn diagrams were
used to show the overlap of identified top candidates of
methylated loci between different pairwise comparisons.
Heatmaps of methylation levels from selected DNA
methylation loci were generated to show the differences
between groups.
For biological insights into top differential methylation
changes in relation to smokers vs. non-smokers and
COPD vs. non-smokers, we implemented a functional
network analysis. Genes annotated from selected differ-
entially methylated probes (DMPs) P value <0.001 were
included in the analysis of gene regulation network. We
used a core analysis of ingenuity pathway analysis (Ingenu-
ity Systems, Inc., Redwood City, CA, USA). Additionally,
statistical analysis of significance for genome-wide DNA
methylation analysis represented as box plots and pyrose-
quencing data analysis included as part of the main figures
and supplemental data were calculated using one-way ana-
lysis of variance (ANOVA) followed by Tukey’s multiple
comparisons test using GraphPad Prism 6. The results are
shown as the mean ± SEM unless otherwise indicated.
P < 0.05 is considered as statistically significant.
Pyrosequencing analysis
Validation of selective gene-specific CpGs identified
from HumanMethylation450 BeadChip analysis was per-
formed using the same genomic DNA used for genome-
wide methylation analysis as described above. We validated
the methylation of five CpG sites (NOS1AP, TNFAIP2, BID,
GABRB1, ATXN7, and THOC7) identified by the 450K
array mentioned above and two other CpG sites [AHRR
(cg21161138) and SERPINA1 (cg02181506)] based on prior
studies [11, 26]. When we designed the assay for pyrose-
quencing of target CpG sites, we included additional CpG
sites along with the CpG site identified based on genome-
wide DNA methylation data for all the selected subset of
genes for pyrosequencing. Forward and reverse primers are
designed using the Pyromark Assay Design Software.
Bisulfite conversion and cleanup of DNA samples were
performed by using EpiTect Fast Bisulfite Conversion
Kits (Qiagen). DNA was amplified in PCR using the
PyroMark PCR kit (Qiagen). Pyrosequencing was per-
formed using the PyroMark Q24 Advanced as per the
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manufacturer’s instructions. Using the PyroMark CpG
Software 2.0, CpG methylation percentages were calcu-
lated based on the height of the T and C peaks at the
methylation site and applying the formula (C/C + T) ×
100. The forward and reverse PCR primers and sequen-
cing primer for specific CpGs are listed (Table 8).
Results
Genome-wide DNA methylation data analysis was per-
formed using lung tissues from eight patients with COPD
(GOLD stages: III–IV) with mean forced expiratory vol-
ume in 1 s, FEV1 predicted (23 ± 4.41), eight smokers with
FEV1 predicted (88.75 ± 4.04) and eight non-smokers
(controls) with normal spirometry (Table 1). There were
no significant differences between non-smokers, smokers,
and patients with COPD based on their sex and age. All
the smokers and patients with COPD had higher pack
years of cigarettes smoked compared to non-smokers
(P < 0.001).
Differential methylation
We hypothesized that genome-wide lung DNA methyla-
tion profiles of smokers and patients with COPD would
be significantly different from non-smokers (controls).
Boxplot was generated using the boxplot function in R.
Boxplot was used to describe the distribution of pre-
processed DNA methylation level (β values). The central
50 percentile of the β values range from 0.35 to 0.90.
The spread of the β values were slightly varied within
each group. No obvious differences between groups were
observed for distribution of β values (Additional file 1:
Figure S1). Differentially methylated probe (DMP) ana-
lysis revealed a total of 10 CpG sites that were possibly
differentially methylated between smokers vs. non-
smokers, a total of 280 CpG sites that were possibly differ-
entially methylated between COPD vs. non-smokers, and
a total of 10 CpG sites that were possibly differentially
methylated between COPD vs. smokers (unadjusted raw
P value P < 0.001) (Additional file 2: Table S1, Additional
file 3: Table S2 and Additional file 4: Table S3). Similarly,
DMP analysis revealed 115 CpG sites (smokers vs. non-
smokers), 1961 CpG sites (COPD vs. non-smokers),
and 136 CpG sites (COPD vs. smokers) (unadjusted raw
P value P < 0.01) (Additional file 5: Table S4, Additional
file 6: Table S5 and Additional file 7: Table S6). Finally,
DMP analysis with unadjusted raw P value P < 0.05
revealed a total of 10,363 CpG sites in smokers vs.
non-smokers, a total of 34,151 CpG sites in COPD
vs. non-smokers, and a total of 11,339 CpG sites that
were differentially methylated between COPD vs. smokers
(Additional file 8: Table S7, Additional file 9: Table S8 and
Additional file 10: Table S9).
Manhattan plot was generated using the Manhattan.
plot function in R. Manhattan plot showed the negative
P values on log10 scale on each chromosome with rela-
tively small unadjusted raw P values corresponding to
larger–log10 (p value). The chromosome-wide distri-
bution of CpG sites and their comparison groups (non-
smokers vs. smokers, non-smokers vs. COPD, and COPD
vs. smokers) were shown (Fig. 1a–c and Tables 2, 3,
and 4). Similarly, volcano plot was generated using the
volcano plot function in limma package in R. Volcano
plot is a scatter plot of log odds ratios vs. log fold
change. The top 10 CpGs sites and associated genes
including others CpG sites that were chosen for valid-
ation by pyrosequencing (NOS1AP, TNFAIP2, BID,
GABRB1, ATXN7, and THOC7) based on their bio-
logical function with corresponding DNA methylation
loci that were differentially methylated between differ-
ent comparison groups are shown in the volcano plots
(Fig. 2a–c and Tables 2, 3, and 4). Venn diagram was
generated using the Venn diagram function in limma
package in R. Venn diagram shows the overlap of DNA
methylation loci that are shared between different com-
parisons (Additional file 1: Figure S2). The total num-
ber of overlapping genes and probes under each
comparison groups shown in Venn diagram were not
the same since a few of these did not annotate to genes
(Additional file 2: Table S1, Additional file 3: Table S2
and Additional file 4: Table S3). Heatmaps were gener-
ated using the heatmap.2 function in the gplot package
in R. We have included the DNA methylation loci and
samples groups (NS, non-smokers; S, smokers, and C,
COPD) for cluster analysis using the hierarchical clus-
tering method. The green color in the heatmap denotes
hyper-methylated loci, and the red color in the heatmap
denotes the hypo-methylated loci. The sample groups
are denoted by different colors. The top 100 genes
along with the genes chosen for validation by pyrose-
quencing were included as part of the cluster analysis
in smoker vs. non-smokers (Fig. 3a), COPD vs. non-
smokers (Fig. 3b), and COPD vs. smokers (Fig. 3c), in-
cluding the list of DMPs (Additional file 11: Table S10,
Additional file 12: Table S11 and Additional file 13:
Table S12).
From genome-wide methylation data, when we com-
pared possible differentially methylated probes and their
associated genes between smokers vs. non-smokers,
results revealed the top 10 CpG sites such as
ANKRD9 (cg14531093), HLA-DRB5 (cg15011943),
TNFAIP2 (cg18620571), ANGPT1 (cg22837763),
FAM8A1 (cg10154826), cg17289692, ATXN7 and THOC7
(cg07753241), CNOT1 (cg01096617), ACTN4 (cg25383568),
and LOC387646 (cg20377766) (Fig. 4 and Table 2).
Similarly, when we compared possible differentially
methylated probes and their associated genes between
COPD vs. non-smokers, results revealed the top 10
CpG sites such as ANGPT1 (cg22837763), PLD1
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Fig. 1 Manhattan plots showing distribution of possible differentially methylated CpG sites identified in this study across chromosomes. a Differential
methylation analysis between smokers and non-smokers presented by chromosomal location (x axis). b Differential methylation analysis between
COPD and non-smokers presented by chromosomal location (x axis). c Differential methylation analysis between COPD and smokers presented by
chromosomal location (x axis). The y axis represents the negative log P value of their association. The genes marked in blue color are the once validated
by pyrosequencing analysis. The black dotted horizontal line indicates the genome-wide significance threshold of P < 0.001. The top candidates in each
pairwise comparison were selected by test statistics and unadjusted P values for comparisons (P < 0.001 is commonly used as a cutoff for relatively
small unadjusted raw P value)
Table 2 Top 10 differentially methylated CpG sites in smokers compared to non-smokers, sorted by P value
CpG site Gene symbol Chromosome aProbe Type P value bGene location of first annotated transcript cIsland location
cg14531093 ANKRD9 14 I 4.04E-06 Body Island
cg15011943 HLA-DRB5 6 II 2.16E-05 Body S_Shelf
cg18620571 TNFAIP2 14 I 3.28E-05 Body Island
cg22837763 ANGPT1 8 II 3.86E-05 Body
cg10154826 FAM8A1 6 II 4.26E-05 1st Exon Island
cg17289692 3 II 5.48E-05
cg07753241 ATXN7;THOC7 3 II 6.74E-05 TSS1500 Island
cg01096617 CNOT1 16 II 7.50E-05 Body
cg25383568 ACTN4 19 I 9.46E-05 Body Island
cg20377766 LOC387646 10 II 9.63E-05 TSS1500 Island
aProbe type I or type II design specified on the assay
bLocation relative to the first listed transcript
cS_ denote the downstream end of the island region
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(cg22920586), NFASC (cg08830492), ACTN4 (cg25383568),
RGS12 (cg05275153), CAV1 (cg15558717), PRKAG2
(cg06746365), JARID2 (cg24408769), HIPK2 (cg14630106),
and MECOM (cg25010400) (Fig. 5 and Table 3). Finally,
when we compared possible differentially methylated
probes and their associated genes between COPD vs.
smokers, results revealed of the top 10 CpG sites 3 were as-
sociated with genes CSMD1 (cg08236285), LOC285830
(cg12035144), and FAM8A1 (cg10154826). The remaining
seven CpG sites did not annotate to genes (cg13835168,
cg12384790, cg27061576, cg23073974, cg0749225,
cg26781321, and cg06723525) (Fig. 6 and Table 4). To
further examine the differential methylation results as-
sociated with smokers vs. non-smokers and COPD vs.
non-smokers, pathway analyses were performed using
IPA. The possible differentially methylated genes identi-
fied with unadjusted raw P value P < 0.001 revealed sig-
nificant enrichment of genes related to top diseases and
biological functions (Tables 5 and 6) including enriched
canonical pathways (Table 7).
Pyrosequencing analysis
Among the significant differentially methylated genes/
probes identified in smokers vs. non-smokers and COPD
vs. non-smokers based on their gene ontology (GO) ana-
lysis that directly relates to the biological functions, we
chose a subset of genes for validation using pyrose-
quencing. In our pyrosequencing validation approach,
the most significant subset of genes with CpG sites iden-
tified from our genome-wide DNA methylation analysis
was selected based on their location (CpG island). It is
evident that CpG island in a gene is associated with high
CG density region (promoter or regulatory element), and
the methylation status of which indirectly co-relates to its
gene expression. Validating the differential methylation
status of the specific subset of genes by pyrosequencing
will further enhances the utility of those suggestive genes
to be developed as a novel epigenetic signatures. Thus,
DNA methylation can be used as a tool for the develop-
ment of epigenetic-based diagnostic and therapeutic strat-
egies in smokers and patients with COPD.
Table 3 Top 10 differentially methylated CpG sites in COPD compared to non-smokers, sorted by P value
CpG site Gene symbol Chromosome aProbe Type P value bGene location of first annotated transcript Island location
cg05275153 RGS12 4 I 2.24E-06 Body
cg06746365 PRKAG2 7 II 2.48E-06 Body
cg08830492 NFASC 1 I 1.24E-06 5UTR Island
cg14630106 HIPK2 7 II 3.35E-06 Body
cg15558717 CAV1 7 II 2.40E-06 Body
cg22837763 ANGPT1 8 II 1.30E-07 Body
cg22920586 PLD1 3 II 5.93E-07 5UTR
cg24408769 JARID2 6 I 3.30E-06 Body
cg25010400 MECOM 3 II 3.64E-06 Body
cg25383568 ACTN4 19 I 1.75E-06 Body Island
aProbe type I or type II design specified on the assay
bLocation relative to the first listed transcript
Table 4 Top 10 differentially methylated CpG sites in COPD compared to smokers, sorted by P value
CpG site Gene symbol Chromosome aProbe Type P value bGene location of first annotated transcript cIsland location
cg06723525 10 II 8.96E-05 S_Shore
cg08236285 CSMD1 8 II 6.95E-05 Body
cg09749225 6 I 8.57E-05 Island
cg10154826 FAM8A1 6 II 9.94E-05 1stExon Island
cg12035144 LOC285830 6 II 7.28E-05 TSS1500 S_Shore
cg12384790 12 II 1.96E-05 N_Shelf
cg13835168 6 II 1.64E-05
cg23073974 2 II 5.27E-05
cg26781321 8 II 8.79E-05
cg27061576 15 II 2.28E-05
aProbe type I or type II design specified on the assay
bLocation relative to the first listed transcript
cN_ and S_ denote the upstream and downstream end of the island region, respectively
Sundar et al. Clinical Epigenetics  (2017) 9:38 Page 6 of 18
In our genome-wide DNA methylation analysis,
NOS1AP (cg26663636), TNFAIP2 (cg18620571),
GABRB1 (cg15393297), and BID (cg01388022) are hyper-
methylated both in smoker and COPD compared to non-
smokers group (Fig. 7). We also selected ATXN7 and
THOC7 genes (cg07753241) to validate since they both
share the promoter (CpG island) that was hypo-
methylated in smoker and COPD in our genome-wide
DNA methylation analysis (Fig. 8). Besides ATXN7 and
THOC7 all the other genes (NOS1AP, TNFAIP2, GABRB1,
and BID) selected for pyrosequencing were significantly
hyper-methylated in CpG island which is located in the
gene body. Additionally, we included AHRR (cg21161138)
[26] and SERPINA1 (cg02181506) [11] which were shown
to be significantly hypo-methylated in smokers and pa-
tients with COPD based on prior studies as part of the
pyrosequencing validation in this study. We designed
pyrosequencing primer sets for the above mentioned
subset of genes (Additional file 1: Figure S3–S9 and
Table 8). Of the five different genes validated by pyrose-
quencing, NOS1AP was significantly hyper-methylated
in smokers and COPD compared to non-smokers group
(Fig. 8). Interestingly, we found that most of the CpG sites
(out of the 11 CpG sites) analyzed for NOS1AP showed sig-
nificant hyper-methylation in smokers and COPD groups
compared to non-smokers. Furthermore, when we com-
bined the methylation percentage from all the 11 CpG sites
for NOS1AP, we found significant hyper-methylation in
smokers and COPD compared to the non-smokers group
(Additional file 1: Figure S10). Pyrosequencing validations
for TNFAIP2 CpG site including additional 10 CpG sites
assayed were not significant both in smokers and COPD
(Additional file 1: Figure S11). Validation for BID CpG site
was not significant in smokers and COPD compared to
Fig. 2 Volcano plots showing possible differentially methylated CpG sites identified in this study. a Differential methylation analysis revealed top
10 CpG sites and their genes significantly associated with smokers with P < 0.001. Difference in mean percent methylation represents the difference in
mean methylation between smokers vs. non-smokers (control). b Differential methylation analysis revealed top 10 CpG sites and their genes
significantly associated with COPD with P < 0.001. Difference in mean percent methylation represents the difference in mean methylation between
COPD vs. non-smokers (control). c Differential methylation analysis revealed CpG sites and their genes significantly associated with COPD compared to
smokers with P < 0.001. Difference in mean percent methylation represents the difference in mean methylation between COPD vs. smokers (control).
The y axis represents the negative log P value of their association. The genes marked in blue color are the once validated by pyrosequencing analysis.
The red and green dotted horizontal lines indicate the genome-wide significance threshold of P < 0.001 and P < 0.05, respectively. The top candidates in
each pairwise comparison were selected by test statistics and unadjusted P values for comparisons (P < 0.001 is commonly used as a cutoff for
relatively small unadjusted raw P value)
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non-smokers groups. Instead, all the additional three CpG
sites that were located close to the identified CpG site
for BID showed significant hyper-methylation in
smokers and COPD compared to the non-smokers
group (Additional file 1: Figure S12). Our pyrosequencing
analysis showed that the CpG site for GABRB1 was
significantly hyper-methylated in smokers, although not
significant in COPD compared to the non-smokers group.
All the additional CpG sites validated for GABRB1 were
not significant in smokers and COPD (Additional file 1:
Figure S12). The CpG sites validated by pyrosequencing
for ATXN7 and THOC7 for hypo-methylation in smokers
and COPD compared to non-smokers group were not sig-
nificant (Additional file 1: Figure S13).
a b
c
Fig. 3 Hierarchical cluster analysis of differentially methylated CpG sites identified in this study. a Heatmap of top 100 differentially methylated
CpG sites in smokers vs. non-smokers group. b Heatmap of top 100 differentially methylated CpG sites in COPD vs. non-smokers group. c Heatmap of
top 100 differentially methylated CpG sites in COPD vs. smokers group. Additionally for cluster analysis, we have also included the five genes that were
chosen for validation for pyrosequencing along with the top 100 genes. The green color in the heatmap denotes hyper-methylated loci, and the red
color in the heatmap denotes the hypo-methylated loci. Target id and gene list for the top 100 differentially methylated probes (a–c) are included in
the Additional file 11: Table S10, Additional file 12: Table S11 and Additional file 13: Table S12
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Discussion
Epigenetic modifications may play a critical role in regu-
lating expression of genes involved in molecular pathways
and cellular processes relevant to the pathogenesis of
COPD [1]. Recently, we have reported cigarette smoke dif-
ferentially regulates gene expression profiles of epigenetic
chromatin modification enzymes and DNA methyltrans-
ferases in vitro in H292 cell and in vivo in mouse lung
[27]. Previous genome-wide DNA methylation studies
were focused on DNA methylation associated with smok-
ing and COPD using various sample types, such as whole
blood, lymphoblasts, pulmonary macrophages, sputum,
buccal, small airway cells, and lung tissues [5–14, 17, 18].
In the present study, we used lung parenchymal tissue
DNA to perform genome-wide DNA methylation analysis
using the Illumina’s Infinium 450K methylation BeadChip
and validated selective CpG sites from a subset of genes
including NOS1AP, BID, and GABRB1 by pyrosequencing
analysis. We have identified several novel target CpG sites
of specific genes by genome-wide methylation analysis
using lung tissue DNA from smokers and patients with
COPD based on their biological functions.
Pathway analysis revealed possible genes differentially
methylated in our genome-wide study among the
smokers and COPD group that belong to cardiovascular
disease and respiratory disease, respectively, under the
disease and disorders categories. Based on their molecu-
lar and cellular functions, the identified top differentially
methylated probes (DMPs) among smokers include cell
morphology, cell-to-cell signaling and interaction, cellu-
lar assembly and organization, cell cycle, and cell death
and survival. Additionally, DMPs among the patients with
COPD showed cellular development, cell death and sur-
vival, cell morphology, cellular assembly and organization,
and cellular function and maintenance as their top mo-
lecular and cellular functions. Further, our pyrosequencing
data from NOS1AP, BID, and GABRB1 CpG sites analysis
validates hyper-methylation in smokers and COPD com-
pared to non-smokers. These genes are part of the relevant
pathways in the pathogenesis of COPD, e.g., oxidative
stress and mitochondrial dysfunction/autophagy. We
speculate that altered DNA methylation status may affect
gene expression of NOS1AP, BID, and GABRB1 genes in
lung tissues of smokers and patients with COPD and per-
turb the key cellular pathways involved in cellular senes-
cence/autophagy/apoptosis. Future studies will address this
issue by validating this hypothesis using the same samples
for both DNA methylation and gene expression analysis.
It is known that promoter hyper-methylation can cause
gene silencing. Hence, the results of our genome wide
Fig. 4 Differentially methylated CpG sites associated with smokers. Differential methylation analysis revealed CpG sites in genes significantly
associated with smokers with a P value less than 0.05. Difference in mean beta values represents the difference in mean methylation between
smokers and non-smokers (controls). The y axis represents the beta value. The gene symbol associated with CpG probes are provided in parenthesis.
Data are represented as a box plot which displays the full range of variation (from min to max), the likely range of variation (the IQR) and a typical value
(the median) for n = 8/group, and the significance determined using one-way ANOVA (Tukey’s multiple comparisons test). *P < 0.05, **P < 0.01,
***P < 0.001, vs. non-smokers; ###P < 0.001 vs. smokers
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analysis may provide insights into the involvement of pos-
sible target genes in the pathogenesis of smoking-related
chronic lung diseases by looking into which genes show
changes in promoter DNA methylation. Among the top
significant genes which are hyper-methylated in smokers
include ANKRD9, HLA-DRB5 TNFAIP2, ANGPT1,
FAM8A1, ATXN7, THOC7, CNOT1, and ACTN4. Simi-
larly, when we compared COPD group with the non-
smokers, all the top differentially methylated CpG sites
significantly hyper-methylated includes ANGPT1, PLD1,
NFASC, ACTN4, RGS12, CAV1, PRKAG2, JARID2, HIPK2,
and MECOM. Some of the top differentially methylated
genes, such as ANKRD9, CAV1, and JARID2, were previ-
ously known to be highly expressed in basal cells [28] sig-
nificantly hyper-methylated in smokers and COPD groups
confirmed by genome-wide DNA methylation analysis. A
recent study suggests that caveolin-1 (Cav1) as a critical
regulatory protein in pathological mechanisms of chronic
inflammatory lung diseases. Loss of CAV1 contributes
to an imbalance in the Th17/Treg cell in patients with
COPD [29]. Additionally, two other genes TNFAIP2
and ANGPT1 are identified to be hyper-methylated as
smoking-responsive genes discovered by microarray
and RNA sequencing approaches [30, 31]. Recently,
CpG island hyper-methylation of ANKRD18B was asso-
ciated with decreased expression of ANKRD18B in lung
cancer tissues and cell lines compared to normal lung
tissues [32]. Chi et al. reported that ANKRD11 was one
among the other genes (ANKHD1 and LGALS2) with
both regulatory DNA methylation sites in circulating
monocytes and their mRNA expression that was associ-
ated with air pollution [33]. Another report showed
HLA-DRB5 gene (major histocompatibility complex,
class II, DR beta 5) among the expression quantitative
trait loci (eQTLs) expressed in neutrophils that may be
involved in immune-recognition/regulation and mito-
chondrial function [34]. Wan et al. has shown association
of genes such as HIPK3(homeodomain-interacting protein
kinase 3), a serine-threonine protein kinase that partici-
pates in cAMP-mediated steroidogenesis involved in the
synthesis and regulation of steroid hormones, was differ-
entially methylated in COPD who were under systemic
steroid use [9]. Furthermore, these CpG sites and loci dif-
ferentially methylated in smokers and COPD can be used
as epigenetic signature in smokers and COPD based on
their methylation status. Overall, several gene families
identified (i.e., ANGPT, ANKRD, HIPK, and HLA-DRB)
among the top differentially methylated CpG sites from
Fig. 5 Differentially methylated CpG sites associated with COPD. Differential methylation analysis revealed CpG sites in genes significantly associated
with COPD with a P value less than 0.05. Difference in mean beta values represents the difference in mean methylation between COPD and
non-smokers (controls). The y axis represents the beta value. The gene symbol associated with CpG probes are provided in parenthesis. Data
are represented as a box plot which displays the full range of variation (from min to max), the likely range of variation (the IQR) and a typical
value (the median) for n = 8/group, and the significance determined using one-way ANOVA (Tukey’s multiple comparisons test). *P < 0.05,
**P < 0.01, ***P < 0.001, vs. non-smokers; #P < 0.05 vs. smokers
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this study have been previously implicated as responsive
genes in smokers and patients with COPD. This is based
on their transcriptomics/DNA methylation data suggest-
ing their role in the pathogenesis of smoking-related
chronic lung diseases including COPD.
Our pyrosequencing data validates DNA methylation
status of three candidate genes (NOS1AP, BID, and
GABRB1) out of five genes that was identified from the
genome-wide DNA methylation analysis. Nitric oxide
synthase 1 adaptor protein (NOS1AP) is a cytosolic pro-
tein that binds to the signaling molecule nNOS (neuronal
nitric oxide synthase) that plays an important role in re-
lieving hemodynamic force, and thereby aids in protecting
the arterial walls from vascular inflammation [35]. It is
known that cardiovascular disease and co-morbidities are
associated with COPD [36], COPD patients have a three-
fold risk of developing ischemic heart disease and lung
cancer compared to smokers without clinical manifest-
ation of COPD. These findings support that vascular dys-
function and systemic inflammation are linked to COPD
[37, 38]. Interestingly, NOS1AP DNA methylation data
from this study is in line with the previous report. Hyper-
methylation of NOS1AP promoter is shown to be associ-
ated with intracranial aneurysm and brain arteriovenous
malformation as a result of regular tobacco use [39]
NOS1AP has been implicated in several human
neurodegenerative diseases, such as cardiovascular dis-
orders (stroke), psychiatric disorders, and post-
traumatic stress disorders [40]. Variation among oxi-
dant stress pathway genes including NOS1AP in recipi-
ents and donors has been shown to be associated with
primary graft dysfunction after lung transplantation
[41]. Earlier studies show association of NOS1AP differ-
ential methylation in smokers without any validation
[42–44]. To our knowledge, ours is the first study to
identify NOS1AP hyper-methylation in lung parenchy-
mal tissues by genome-wide DNA methylation and py-
rosequencing analysis showing association of nNOS with
smokers and patients with COPD who are at risk to car-
diovascular diseases (co-morbidities).
Recently, we and others have shown role of mitochon-
drial dysfunction (defective mitophagy) in cigarette
smoke-induced cellular senescence in lung cells (epithe-
lial and fibroblasts) in vitro and mouse lungs in vivo as
well as in smokers and patients with COPD [45, 46].
BID (BH3-interacting domain death agonist) protein is a
member of the BCL-2 family of cell death regulators.
BID functions in mitochondria for apoptosis during mi-
totic arrest [47] and engages a ROS-dependent, local
inter-mitochondrial potentiation mechanism that ampli-
fies the apoptotic signal [48]. BID CpG site was signifi-
cantly hyper-methylated among the smokers and COPD
Fig. 6 Differentially methylated CpG sites associated with COPD vs. smokers. Differential methylation analysis revealed CpG sites in genes
significantly associated with smokers vs. COPD with a P value less than 0.05. Difference in mean beta values represents the difference in mean
methylation between smokers and COPD. The y axis represents the beta value. The gene symbol associated with CpG probes are provided in
parenthesis. Data are represented as a box plot which displays the full range of variation (from min to max), the likely range of variation (the IQR)
and a typical value (the median) for n = 8/group, and the significance determined using one-way ANOVA (Tukey’s multiple comparisons test).
*P < 0.05, **P < 0.01, vs. non-smokers; ##P < 0.01, ###P < 0.001 vs. smokers
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group in the CpG island based on our genome-wide
DNA methylation analysis. Our DNA methylation for
BID CpG site directly or indirectly affirms the involve-
ment of apoptotic mechanism including mitochondrial
dysfunction role in the pathogenesis of COPD [49, 50].
GABRB1 (gamma-aminobutyric acid type A receptor
beta1 subunit) gene encodes for beta 1 subunit of the
GABA A receptor, which is responsible for mediating
inhibitory neurotransmission in the thalamus [51]. A
previous report shows its role in alveolar fluid homeo-
stasis of alveolar epithelial type II cells [52]. Gene ex-
pression changes caused by GABAergic system during
smoking resulted in marked upregulation of GAD67 ex-
pression in both the large and small airway epithelium
of healthy smokers compared to healthy non-smokers.
This altered GAD67 expression was significantly
Table 5 Top diseases and biological functions associated with differentially methylated genes between smokers vs. non-smokers
Diseases and disorders P value No. of molecules
Hereditary disorder 1.44E-02–8.85E-05 3
Organismal injury and abnormalities 4.84E-02–8.85E-05 8
Renal and urological disease 2.82E-02–8.85E-05 2
Cancer 4.84E-02–3.80E-04 8
Cardiovascular disease 3.45E-02–3.803E-04 1
Molecular and cellular functions P value No. of molecules
Cell morphology 3.48E-02–3.80E-04 2
Cell-to-cell signaling and interaction 4.07E-02–3.80E-04 2
Cellular assembly and organization 4.44E-02–3.80E-04 3
Cell cycle 3.42E-03–7.61E-04 2
Cell death and survival 4.45E-02–7.61E-04 2
Physiological system development and function P value No. of molecules
Cardiovascular system development and function 4.07E-02–3.80E-04 3
Embryonic development 3.26E-02–3.80E-04 4
Lymphoid tissue structure and development 6.07E-02–3.80E-04 1
Organismal development 2.67E-02–3.80E-04 3
Organ morphology 2.52E-02–3.80E-04 3
Table 6 Top diseases and biological functions associated with differentially methylated genes between COPD vs. non-smokers
Diseases and disorders P value No. of molecules
Organismal injury and abnormalities 7.91E-03–1.41E-04 40
Cancer 7.91E-03–1.53E-04 32
Connective tissue disorders 7.91E-03–3.69E-04 8
Dermatological diseases and conditions 7.91E-03–5.12E-04 13
Respiratory disease 7.91E-03–5.43E-04 9
Molecular and cellular functions P value No. of molecules
Cellular development 7.91E-03–3.40E-10 58
Cell death and survival 7.91E-03–1.55E-07 49
Cell morphology 7.91E-03–3.15E-07 43
Cellular assembly and organization 7.91E-03–3.15E-07 32
Cellular function and maintenance 7.91E-03–3.15E-07 44
Physiological system development and function P value No. of molecules
Nervous system development and function 7.91E-03–3.33E-09 49
Tissue morphology 7.91E-03–2.60E-07 49
Tissue development 7.91E-03–3.15E-07 56
Organ morphology 7.91E-03–4.93E-07 32
Organismal development 7.91E-03–4.93E-07 60
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correlated with increased MUC5AC gene expression
during smoking [53]. Our genome-wide DNA methyla-
tion data show significant hyper-methylation of
GABRB1 in smokers and COPD. Nicotine can affect
gene expression of DNA methyltransferase 1 (DNMT1)
that directly or indirectly influences the promoter
methylation status of GABAergic neurons, thereby
providing a plausible link to nicotine addiction [54].
However, it remains unclear how GABRB1 functions as
ligand-gated chloride channel during cigarette smoke-
induced pulmonary toxic responses in the lungs of
smokers and patients with COPD. Likewise, under-
standing the DNA methylation signature in lung tis-
sues of smokers and COPD patients will enable us to
discover the possibility of using selective epigenetic-
based drugs that can attenuate progression of COPD
in smokers.
In this study, we also included Serpin family A mem-
ber 1 (SERPINA1) CpG site (cg02181506) and aryl
hydrocarbon receptor repressor (AHRR) CpG site
(cg21161138) for analysis along with the other CpG
Table 7 Canonical pathways in ingenuity pathway analysis
associated with differentially methylated genes between
smokers vs. non-smokers and COPD vs. non-smokers
Smokers vs. non-smokers
Canonical pathways P value Overlap
B cell development 1.25E-02 3.0% 1/33
Antigen presentation pathway 1.40E-02 2.7% 1/37
Autoimmune thyroid disease signaling 1.77E-02 2.1% 1/47
Graft-vs.-host disease signaling 1.81E-02 2.1% 1/48
Nur77 signaling in T lymphocytes 2.15E-02 1.8% 1/57
COPD vs. non-smokers
Canonical pathways P value Overlap
G Beta gamma signaling 5.35E-06 8.1% 7/86
GNRH signaling 6.42E-06 6.5% 8/124
Molecular mechanisms of cancer 6.98E-06 3.6% 13/366
Role of NFAT in cardiac hypertrophy 1.82E-05 4.8% 9/187
nNOS signaling in neurons 2.74E-05 11.1% 5/45
Fig. 7 Differentially methylated CpG sites identified from genome-wide methylation profiling for pyrosequencing validation. Differential methylation
analysis revealed CpG sites in genes significantly associated with smokers and COPD compared to non-smokers with a P value less than 0.05. Difference
in mean beta values represents the difference in mean methylation between smokers and COPD compared to non-smokers (controls). The y
axis represents the beta value. The gene symbol associated with CpG probes are provided in parenthesis. Data are represented as a box plot
which displays the full range of variation (from min to max), the likely range of variation (the IQR) and a typical value (the median) for n = 8/group, and
the significance determined using one-way ANOVA (Tukey’s multiple comparisons test). *P < 0.05, **P < 0.01, vs. non-smokers
Sundar et al. Clinical Epigenetics  (2017) 9:38 Page 13 of 18
sites for validation even though they were not identified
in our genome-wide methylation analysis. Surprisingly,
our pyrosequencing data for SERPINA1 and AHRR
hypo-methylation in smokers and patients with COPD
did not show significant changes. SERPINA1 encodes
for alpha-1-antitrypsin deficiency that contributes to
the genetic susceptibility of COPD. Previously, SERPINA1
hypo-methylation using whole blood DNA has been
shown in patients with COPD correlated with lower lung
function [11]. In this study, pyrosequencing analysis for
SERPINA1 showed correlation in the methylation status
(methylation percentages) among the non-smoker groups.
However, we were unable to see any significant hypo-
methylation of SERPINA1 CpG site in smokers and COPD
groups compared to non-smokers. Similarly, smoking-
induced DNA methylation alteration in AHRR has been
evidently documented using DNA from lymphoblasts, al-
veolar macrophages, WBCs, and whole blood, suggesting
Fig. 8 Pyrosequencing validation of CpG sites identified in genome-wide DNA methylation analysis. NOS1AP locus cg2663636, TNFAIP2 locus
cg18620571, BID locus cg01388022, GABRB1 locus cg15393297, and ATXN7 and THOC7 locus cg07753241 were validated along with AHRR locus
cg21161138 and SERPINA1 locus cg02181506. Boxplots represent pyrosequencing methylation percentages between smokers and COPD compared to
non-smokers control. Data are represented as box plot which displays the full range of variation (from min to max), the likely range of variation (the
IQR) and a typical value (the median) for n = 8/group, and the significance determined using one-way ANOVA (Tukey’s multiple comparisons
test). *P < 0.05, **P < 0.01, vs. non-smokers
Table 8 CpG pyrosequencing primer sequences
Gene Forward primer 5′ to 3′ Reverse primer 3′ to 5′
NOS1AP (cg26663636) TGTTTGGTGAAGTTGGAGTGT aCCCAATTCCTACCTCTACAAAACATTCA
Sequencing primer: GGTTTGGAGTTTATTAAGTT
TNFAIP2 (cg18620571) GTTAGAGTAAGGTGGAGG aCCAAATCCTCCTTCATAATAC
Sequencing primer: AGAGTAAGGTGGAGG
BID (cg01388022) GAGTTAAATAATGGGTGTTTATGGAT aTAACCCAACACTAACTATATCACCA
Sequencing primer: ATGGAGAGAGTAGGT
GABRB1 (cg15393297) aGTTAATGAAAATAGGTAAAGGTTTTGTAAT AACCACTTATCTATAAAATTCACATC
Sequencing primer: CTATCATAAAAATACATAATAACC
ATXN7/THOC7 (cg07753241) aTAGGGGTTTTAGGGGAGGTTTAG CTCCTCCTCCATAACTATTTACC
Sequencing primer: ACTACATTATAAAAATTTAACCT
AHRR (cg21161138) GGTTGGTGGTGTAGGATATATT aGACGGGACACCGCTGATCGTTTAACCCATCCTACCCAAATCCTAATAAT
Sequencing primer: GGTTTTAGGTTTAGGGA
SERPINA1 (cg02181506) TTTTGGTTTAGTTTAGGATTTTGAGG aAAACACTATACCCAAAACATACACTAC
Sequencing primer: GGATTTTGAGGGTTGTT
aBiotin-labeled: biotinylated primer
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the role of epigenetic effects mediated by CS on carcino-
genesis and other related co-morbidities in a tissue-
independent manner [6, 26, 55–58]. These studies have
implicated the role of CS-mediated oxidative stress and
inflammatory response associated with DNA methylation
(hypo-methylation) in SERPINA1 and AHRR CpG sites.
Our observations regarding the lack of correlation ob-
served in SERPINA1 and AHRR hypo-methylation in
smokers and COPD could be due to limited sample size,
tissue heterogeneity (cell-type present in lung parenchy-
mal tissue), and genetic variants present in our samples.
We were unable to validate DNA methylation changes of
the TNFAIP2 and ATXN7/THOC genes using pyrose-
quencing. The exact reason for lack on reproducibility of
findings is not known. This inconsistency shows that vali-
dations are important to confirm the array-based DNA
methylation analysis. Therefore, it is important to validate
the identified CpG sites using another technique which is
very specific for the target CpG sites, such as the pyrose-
quencing assays as used in this study.
In this study, we also identified DMR of oxidative
stress-related genes, steroid-responsive genes, and cellu-
lar signaling genes linked to molecular and cellular func-
tions (cell death and survival pathways). Previous studies
have provided evidence that cigarette smoking plays an
important role in epigenetic regulation of oxidative stress
genes (e.g., glutamate-cysteine ligase catalytic subunit
(GCLC)) and immune-related genes (IL-12RB2 and
WIF-1) involved in the pathogenesis of COPD and
lung cancer (CCDC37, and MAP1B) [5, 11, 59–61].
Earlier studies have shown site-specific DNA methyla-
tion during steroid resistance in COPD, in smokers
even after cessation (e.g., Factor II receptor-like 3
(F2RL3) and G-protein-coupled receptor 15 (GPR15)),
and in newborns affected by maternal smoking (in
utero, or early life exposure) leading to complications
later in life [9, 10, 16]. Similarly, promoter methylation
of p16 (CDKN2A) and GATA4 in sputum DNA from
smokers showed significant correlation with decline in
lung function [7]. Based on our observations and prior
studies, we suggest DNA methylation does play an im-
portant role in regulation of oxidative stress, pro-
inflammatory responses, and systemic steroid expos-
ure in COPD [5, 9, 12].
Our study has some limitations, such as limited number
of human lung tissues used and cellular heterogeneity/
specific lung cell types which are affected by chronic
cigarette smoking including the statistical analysis used
for genome-wide DNA methylation analysis. However,
this study is unique as it deals with parenchymal lung tis-
sues which are involved in the pathogenesis of COPD.
Further, our global DNA methylation data are indeed vali-
dated by pyrosequencing for the identified target genes.
Future studies will additionally validate the identified
genes using a larger cohort so as to determine the utility
of suggestive genes as novel epigenetic signatures in
smokers and patients with COPD.
Conclusions
In conclusion, we found novel genes/pathways associated
with possible differential DNA methylation in smokers
and patients with COPD using the Infinium Human-
Methylation450 BeadChip. Based on genome-wide DNA
methylation and functional network analysis, selective
CpG sites (NOS1AP, BID, and GABRB1) differentially
methylated in smokers and COPD compared to non-
smokers were validated by pyrosequencing. However, fu-
ture studies will further validate differential methylation of
target genes and their gene expression signatures in lung
tissues from non-smokers, smokers, and patients with
COPD. Overall, some of the top differentially methylated
probes/genes identified in this study may be used as lung
tissue-specific epigenetic signatures to stratify smoking
exposure and predict the risk of developing smoking-
related chronic lung diseases including COPD, COPD-
exacerbations, and lung cancer after further validation
of the suggested genes in a larger cohort. Further, a
comprehensive, systematic assembly of COPD-related
gene deregulation is required to integrate existing
epigenome-wide DNA methylome and transcriptome
signatures as they relate to COPD phenotypes and ul-
timately merge these data across platforms into a sys-
tems biology paradigm in COPD pathogenesis and its
exacerbations.
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